Heterocyclic compounds as prmt5 inhibitors

A compound represented by a formula:

• or a pharmaceutically acceptable salt thereof;
• wherein
• is an optionally substituted 9-membered bicyclic aromatic heterocyclic ring system containing 1, 2, 3, 4, 5, or 6 ring nitrogen atoms;
• is an optionally substituted fused bicyclic or tricyclic heterocyclic ring system containing 1, 2, 3, 4, 5, or 6 ring heteroatoms independently selected from N, O and S;
• X is —O—, —CH2-, or —CF2-;
• L is optionally substituted C1-3 hydrocarbylene, optionally substituted —O—C1-2 hydrocarbylene-, optionally substituted —S—C1-2 hydrocarbylene-, or optionally substituted —NRA—C1-2 hydrocarbylene-;
• and
• RA is H, C1-6 hydrocarbyl, C1-6 heteroaryl, C1-6 heterocycloalkyl, —C(O)—C1-6 alkyl, —C(O)NH—C1-6 alkyl, or —C(O)OC1-6 alkyl.